4 Nov 2016 15:52
Proteome Sciences plc
(the "Company")
Director/PDMR Shareholding & Total Voting Rights
Proteome Sciences plc (AIM:PRM) announces that further to the announcement on 31 October 2016 regarding a placing (the "Placing") to raise £3.3 million, the first tranche of 45,593,346 ( new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") have today been admitted to trading on AIM ("Admission").
Jeremy Haigh, Chief Executive Officer of the Company, and Roger McDowell, Non-Executive Director of the Company, both participated in the Placing. The number of Placing Shares purchased by the Directors and their beneficial interest in the capital of the Company is set out below:
No. of new Ordinary Shares purchased | Resultant number of Ordinary Shares following the Placing | Interest in total issued share capital following the Placing | |
Jeremy Haigh | 400,000 | 400,000 | 0.15% |
Roger McDowell | 2,000,000 | 2,500,000 | 0.91% |
Following Admission, the Company's issued share capital is 273,660,078 Ordinary Shares. The above figure of 273,660,078 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Jeremy Haigh | ||||
2. | Reason for the Notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Proteome Sciences plc | ||||
b) | LEI | n/a | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 1p each | ||||
Identification code | GB0003104196 | |||||
b) | Nature of the transaction | Subscription to purchase Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: · Aggregated volume · Price |
400,000 Ordinary Shares of 1 pence each purchased at 5 pence per Ordinary Share | ||||
e) | Date of the transaction | 4 November 2016 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Roger McDowell | ||||
2. | Reason for the Notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Proteome Sciences plc | ||||
b) | LEI | n/a | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 1p each | ||||
Identification code | GB0003104196 | |||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: · Aggregated volume · Price |
2,000,000 Ordinary Shares of 1 pence each purchased at 5 pence per Ordinary Share | ||||
e) | Date of the transaction | 4 November 2016 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
Proteome (PRM)